SCHEMBL1744566

SCHEMBL1744566

O=Cc1ccc(Oc2ccc(OC(F)(F)F)cc2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP10 Q53GL7 1/20 0.50
PARP3 Q9Y6F1 1/20 0.50
ALDH1A1 P00352 3/20 0.47
KDM4E B2RXH2 3/20 0.47
LMNA P02545 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
CYP2A6 P11509 1/20 0.47
PIM1 P11309 1/20 0.46
PIM2 Q9P1W9 1/20 0.46
EPHX2 P34913 3/20 0.45
FAAH O00519 2/20 0.45
DRD1 P21728 1/20 0.43
ALDH1A3 P47895 1/20 0.42
MMP2 P08253 4/20 0.42
MMP9 P14780 4/20 0.42
MMP14 P50281 1/20 0.42
MMP1 P03956 2/20 0.42
STS P08842 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
CYP2D6 P10635 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL97114 0.94 ALDH1A1 (0.52) PARP10PARP3ALDH1A1KDM4ELMNA
Hydrochloric Acid SCHEMBL3539828 0.92 ALDH1A1 (0.50) PARP10PARP3ALDH1A1KDM4ELMNA
SCHEMBL3464474 0.88 CYP2D6 (0.48) ALDH1A1KDM4ELMNASMN1; SMN2CYP2A6
SCHEMBL505301 0.88 DRD1 (0.56) ALDH1A1CYP2A6PIM1PIM2EPHX2
SCHEMBL3464472 0.88 CYP2D6 (0.48) ALDH1A1KDM4ELMNASMN1; SMN2CYP2A6
SCHEMBL9270287 0.86 ALDH1A1 (0.45) PARP10PARP3ALDH1A1KDM4ELMNA
SCHEMBL31374872 0.86 ALDH1A1 (0.45) PARP10PARP3ALDH1A1KDM4ELMNA
SCHEMBL9607433 0.85 ALDH1A1 (0.49) ALDH1A1LMNASMN1; SMN2CYP2A6PIM1
SCHEMBL20805839 0.84 EPHX2 (0.71) ALDH1A1EPHX2FAAH
SCHEMBL24512561 0.84 PARP10 (0.41) PARP10PARP3ALDH1A1KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4727923-A1 TETRAHYDROACRIDINONE ANALOGUES FOR TREATMENT AND PREVENTION OF MALARIA University of Georgia Research Foundation, Inc. (US) 2026-04-22 EP disclosed
US-20260098012-A1 TETRAHYDROACRIDINONE ANALOGUES FOR TREATMENT AND PREVENTION OF MALARIA UNIV GEORGIA (US) 2026-04-09 US disclosed
WO-2024258904-A1 TETRAHYDROACRIDINONE ANALOGUES FOR TREATMENT AND PREVENTION OF MALARIA UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2024-12-19 WO disclosed
CN-112341396-B Novel monoacylglycerol esterase inhibitor and preparation method and application thereof 四川大学华西医院 2022-07-26 CN disclosed
US-20220185815-A1 PYRROLOPYRAZOLE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2022-06-16 US disclosed
CN-113543852-A Pyrrolopyrazole derivatives 第一三共株式会社 2021-10-22 CN disclosed
CN-112341396-A Novel monoacylglycerol esterase inhibitor and preparation method and application thereof 四川大学华西医院 2021-02-09 CN disclosed
US-10020456-B2 Ether-based polymers as photo-crosslinkable dielectrics BASF SE (DE) 2018-07-10 US disclosed
US-20170250358-A1 ETHER-BASED POLYMERS AS PHOTO-CROSSLINKABLE DIELECTRICS BASF SE (DE) 2017-08-31 US disclosed
US-20170250358-A1 ETHER-BASED POLYMERS AS PHOTO-CROSSLINKABLE DIELECTRICS BASF SE (DE) 2017-08-31 US disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
EP-2272817-A1 PAI-1 INHIBITOR Institute of Medicinal Molecular Design, Inc. (JP) 2011-01-12 EP disclosed
US-20090312315-A1 PAI-1 INHIBITOR INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-12-17 US disclosed
US-20090312315-A1 PAI-1 INHIBITOR INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-12-17 US disclosed
WO-2009125606-A1 PAI-1 INHIBITOR 株式会社医薬分子設計研究所 (JP) 2009-10-15 WO disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
EP-1559422-A1 RECEPTOR FUNCTION CONTROLLING AGENT Takeda Pharmaceutical Company Limited (JP) 2005-08-03 EP disclosed
US-5403934-A Heterocyclic compounds BURROUGHS WELLCOME CO. (US) 1995-04-04 US disclosed
WO-1991013873-A1 HETEROCYCLIC COMPOUNDS THE WELLCOME FOUNDATION LIMITED (GB) 1991-09-19 WO disclosed
EP-0447164-A1 Heterocyclic compounds THE WELLCOME FOUNDATION LIMITED (GB) 1991-09-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260098012-A1 TETRAHYDROACRIDINONE ANALOGUES FOR TREATMENT AND PREVENTION OF MALARIA CD47, SLC11A2, G6PD PARP10 761/4885PARP3 366/4885ALDH1A1 873/4885
US-20220185815-A1 PYRROLOPYRAZOLE DERIVATIVE PTDSS1, PTDSS2, SMPD1 PARP10 356/4885PARP3 854/4885ALDH1A1 2761/4885
US-20090012093-A1 Receptor Function Regulator GPR119, GIPR, INSR PARP10 2166/4885PARP3 4475/4885ALDH1A1 4258/4885
US-20090312315-A1 PAI-1 INHIBITOR SERPINC1, SERPINE1, SERPINH1 PARP10 808/4885PARP3 866/4885ALDH1A1 1168/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.